
CLAIMS:

1. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides and comprises a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO: 1; and wherein the conjugate group comprises:



2. The compound of claim 1, wherein the modified oligonucleotide comprises at least one modified sugar.

3. The compound of claim 2, wherein at least one modified sugar is a bicyclic sugar.

4. The compound of either one of claims 2 or 3, wherein at least one modified sugar comprises a 2'-O-methoxyethyl, a constrained ethyl, a 3'-fluoro-HNA or a 4'- $(CH_2)_n$-O-2' bridge, wherein n is 1 or 2.

5. The compound of claim 2, wherein at least one modified sugar is 2'-O-methoxyethyl.

6. The compound of any one of claims 1-5, wherein at least one nucleoside comprises a modified nucleobase.

7. The compound of claim 6, wherein the modified nucleobase is a 5-methylcytosine.

8. The compound of any one of claims 1-7, wherein the conjugate group is linked to the modified oligonucleotide at the 5' end of the modified oligonucleotide.

9. The compound of any one of claims 1-7, wherein the conjugate group is linked to the modified oligonucleotide at the 3' end of the modified oligonucleotide.

10. The compound of any one of claims 1-9, wherein each internucleoside linkage of the modified oligonucleotide is selected from a phosphodiester internucleoside linkage and a phosphorothioate internucleoside linkage.

11. The compound of claim 10, wherein the modified oligonucleotide comprises at least 5 phosphodiester internucleoside linkages.

12. The compound of claim 10, wherein the modified oligonucleotide comprises at least two phosphorothioate internucleoside linkages.

13. The compound of any one of claims 1-12, wherein the modified oligonucleotide is single-stranded.

14. The compound of any one of claims 1-12, wherein the modified oligonucleotide is double stranded.

15. The compound of any one of claims 1-14, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

16. The compound of claim 15, wherein each internucleoside linkage in the gap segment of the modified oligonucleotide is a phosphorothioate linkage.

17. The compound of claim 16, wherein the modified oligonucleotide further comprises at least one phosphorothioate internucleoside linkage in each wing segment.

18. The compound of any one of claims 1-17, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.

19. The compound of any one of claims 1-17, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to SEQ ID NO: 1.

20. The compound of any one of claims 1-17, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary to SEQ ID NO: 1.

21. The compound of any one of claims 1-20, wherein the modified oligonucleotide comprises the nucleobase sequence of any of SEQ ID NOs: 3-11.

22. The compound of any one of claims 1-20, wherein the modified oligonucleotide consists of linked nucleosides consisting of the nucleobase sequence of any of SEQ ID NOs: 3-11.

23. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 3, and wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, and wherein each cytosine residue is a 5-methylcytosine.

24. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 4, and wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, and wherein each cytosine residue is a 5-methylcytosine.

25. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of any of SEQ ID NOs: 7, 6, or 8, and wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;

a 5' wing segment consisting of 6 linked nucleosides; and

a 3' wing segment consisting of 4 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, and wherein each cytosine residue is a 5-methylcytosine.

26. The compound of claim 1, wherein the modified oligonucleotide consists of 17 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 5, and wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;

a 5' wing segment consisting of 3 linked nucleosides; and

a 3' wing segment consisting of 4 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, and wherein each cytosine residue is a 5-methylcytosine.

27. The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 10, and wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;

a 5' wing segment consisting of 2 linked nucleosides; and

a 3' wing segment consisting of 4 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the 2 linked nucleosides of the 5' wing segment comprise a 2'-O-methoxyethyl sugar and a constrained ethyl sugar in the 5' to 3' direction; wherein the 4 linked nucleosides of the 3' wing segment comprise a constrained ethyl sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; and wherein each cytosine residue is a 5-methylcytosine.

28. The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 9, and wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;

a 5' wing segment consisting of 3 linked nucleosides; and

a 3' wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the 3 linked nucleosides of the 5' wing segment comprise a 2'-O-methoxyethyl sugar, a constrained ethyl sugar, and a constrained ethyl sugar in the 5' to 3' direction; wherein the 3 linked nucleosides of the 3' wing segment comprise a constrained ethyl sugar, a constrained ethyl sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; and wherein each cytosine residue is a 5-methylcytosine.

29. The compound of claim 1, wherein the modified oligonucleotide consists of 18 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 11, and wherein the modified oligonucleotide comprises:

a gap segment consisting of 8 linked deoxynucleosides;

a 5' wing segment consisting of 5 linked nucleosides; and

a 3' wing segment consisting of 5 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the 5 linked nucleosides of the 5' wing segment comprise a constrained ethyl sugar, a deoxy sugar, a constrained ethyl sugar, a deoxy sugar, and a constrained ethyl sugar in the 5' to 3' direction; wherein each of the 5 linked nucleosides of the 3' wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each cytosine residue is a 5-methylcytosine.


30. The compound of any one of claims 23-29, wherein each internucleoside linkage in the gap segment of the modified oligonucleotide is a phosphorothioate linkage.

31. The compound of claim 30, wherein the modified oligonucleotide further comprises at least one phosphorothioate internucleoside linkage in each wing segment.

32. The compound of any one of claims 23-29, wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage.

33. The compound of any one of claims 23-32, wherein the wherein the modified oligonucleotide is single-stranded.

34. The compound of claim 1, wherein the compound consists of the formula:



, or a pharmaceutically acceptable salt thereof.

35. A composition comprising the compound of any one of claims 1-34 and a pharmaceutically acceptable carrier or diluent.

36. Use of the compound of any one of claims 1-34, or the composition of claim 35, in the manufacture of a medicament for treating a HBV-related disease, disorder or condition in a subject, wherein the disease, disorder or condition is jaundice, liver inflammation, liver fibrosis, inflammation, liver cirrhosis, liver failure, liver cancer, diffuse hepatocellular

inflammatory disease, hemophagocytic syndrome, serum hepatitis, HBV viremia, or liver disease–related transplantation.

37. Use of the compound of any one of claims 1-34, or the composition of claim 35, in the manufacture of a medicament for reducing HBV antigen levels in a subject infected with HBV.

38. The use according to claim 37, wherein the HBV antigen is HBsAG or HBeAG.